Is alpha-synuclein loss-of-function a contributor to parkinsonian pathology? Evidence from non-human primates

Frontiers in Neuroscience

Volumn 10, Issue JAN, 2016, Pages

  Collier, Timothy J ^a,b   Eugene Redmond, D ^c,d   Steece Collier, Kathy ^a,b   Lipton, Jack W ^a,b   Manfredsson, Fredric P ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Hauenstein Neuroscience Center   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Axion Research Foundation   (United States)

Author keywords

Alpha synuclein; Dopamine; Non human primates; Parkinson's disease; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN;

ARTICLE; DOPAMINERGIC NERVE CELL; GAIN OF FUNCTION MUTATION; LEWY BODY; LOSS OF FUNCTION MUTATION; MESENCEPHALON; NERVE DEGENERATION; NEURITE; NONHUMAN; PARKINSONISM; PRESYNAPTIC POTENTIAL; PRIMATE; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN LOCALIZATION; STRIATONIGRAL DEGENERATION; SYNAPSE;

EID: 84958037840     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2016.00012     Document Type: Article

References (41)

1. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., et al. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252. doi: 10.1016/S0896-6273(00)80886-7.
2. Al-Wandi, A., Ninkina, N., Millership, S., Williamson, S. J., Jones, P. A., and Buchman, V. L. (2010). Absence of alpha-synuclein affects dopamine metabolism and synaptic markers of aging in the striatum of aging mice. Neurobiol. Aging 31, 796-804. doi: 10.1016/j.neurobiolaging.2008.11.001.
3. Anwar, S., Peters, O., Millership, S., Ninkina, N., Doig, N., Connor-Robson, N., et al. (2011). Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J. Neurosci. 31, 7264-7274. doi: 10.1523/JNEUROSCI.6194-10.2011.
4. Chadchankar, H., Ihalainen, J., Tanila, H., and Yavich, L. (2011). Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain. Res. 1382, 37-44. doi: 10.1016/j.brainres.2011.01.064.
5. Chesselet, M.-F., and Richter, F. (2011). Modelling of Parkinson's disease in mice. Lancet Neurol. 10, 1108-1118. doi: 10.1016/S1474-4422(11)70227-7.
6. Chu, Y., and Kordower, J. H. (2007). Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol. Dis. 25, 134-149. doi: 10.1016/j.nbd.2006.08.021.
7. Cookson, M. R. (2006). Hero versus antihero: the multiple roles of alpha-synuclein in neurodegeneration. Exp. Neurol. 199, 238-242. doi: 10.1016/j.expneurol.2006.03.011.
8. Crabtree, D. M., and Zhang, J. (2012). Genetically engineered mouse models of Parkinson's disease. Brain Res. Bull. 88, 13-32. doi: 10.1016/j.brainresbull.2011.07.019.
9. Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., and Lee, V. M. (2002). Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521-533. doi: 10.1016/S0896-6273(02)00682-7.
10. Gibb, W. R. G., and Lees, A. J. (1991). Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 54, 388-396. doi: 10.1136/jnnp.54.5.388.
11. Gorbatyuk, O. S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A. S., Sullivan, L. F., et al. (2010). In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol. Ther. 18, 1450-1457. doi: 10.1038/mt.2010.115.
12. Ibanez, P., Bonnet, S. M., Debarges, B., Lohmann, E., Tison, F., Pollak, P., et al. (2004). Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169-1171. doi: 10.1016/S0140-6736(04)17104-3.
13. Kanaan, N. M., and Manfredsson, F. P. (2012). Loss of functional alpha-synuclein: a toxic event in Parkinson's disease? J. Parkinsons Dis. 2, 249-267. doi: 10.3233/JPD-012138.
14. Kish, S. J., Shannak, K., and Hornykiewicz, O. (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876-880. doi: 10.1056/NEJM198804073181402.
15. Klein, R. L., King, M. A., Hamby, M. E., and Meyer, E. M. (2002). Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13, 605-612. doi: 10.1089/10430340252837206.
16. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108. doi: 10.1038/ng0298-106.
17. Kuhn, M., Haebig, K., Bonin, M., Ninkina, N., Buchman, V. L., Poths, S., et al. (2007). Whole genome expression analyses of single-and double-knock-out mice implicate partially overlapping functions of alpha-and gamma-synuclein. Neurogenetics 8, 71-81. doi: 10.1007/s10048-007-0079-z.
18. Lin, X., Parisiadou, L., Sgobio, C., Liu, G., Yu, J., Sun, L., et al. (2012). Conditional expression of Parkinson disease-related mutant alpha-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J. Neurosci. 32, 9248-9264. doi: 10.1523/JNEUROSCI.1731-12.2012.
19. Locascio, J. J., Eberly, S., Liao, Z., Liu, G., Hoesing, A. N., Duong, K., et al. (2015). Association between alpha-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain 138, 2659-2671. doi: 10.1093/brain/awv202.
20. Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J. Q., et al. (2012). Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953. doi: 10.1126/science.1227157.
21. Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S., and Selkoe, D. J. (2014). Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 289, 21490-21507. doi: 10.1074/jbc. M113.545749.
22. Malek, N., Swallow, D., Grosset, K. A., Anichtchik, O., Spillantini, M., and Grosset, D. G. (2014). Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease-a systematic review. Acta Scand. Neurol. 130, 59-72. doi: 10.1111/ane.12247.
23. Manning-Bog, A. B., McCormack, A. L., Purisai, M. G., Bolin, L. M., and DiMonte, D. A. (2003). Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23, 3095-3099.
24. Maries, E., Dass, B., Collier, T. J., Kordower, J. H., and Steece-Collier, K. (2003). The role of alpha-synuclein in Parkinson's disease: Insights from animal models. Nat. Rev. Neurosci. 4, 727-738. doi: 10.1038/nrn1199.
25. Markopoulou, K., Biernacka, J. M., Armasu, S. M., Anderson, K. J., Ahlskog, J. E., Chase, B. A., et al. (2014). Does alpha-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? Parkinsonism Relat. Disord. 20, 584-589. doi: 10.1016/j.parkreldis.2014.02.021.
26. Musgrove, R. E., King, A. E., and Dickson, T. C. (2011). Neuroprotective upregulation of endogenous alpha-synuclein precedes ubiquitination in cultured dopaminergic neurons. Neurotox. Res. 19, 592-602. doi: 10.1007/s12640-010-9207-x.
27. Osterberg, V. R., Spinelli, K. J., Weston, L. J., Luk, K. C., Woltjer, R. L., and Unni, V. K. (2015). Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 10, 1252-1260. doi: 10.1016/j.celrep.2015.01.060.
28. Pacheco, C. R., Morales, C. N., Ramirez, A. E., Munoz, F. J., Gallegos, S. S., Caviedes, P. A., et al. (2015). Extracellular alpha-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. J. Neurochem. 132, 731-741. doi: 10.1111/jnc.13060.
29. Perez, R. G., and Hastings, T. G. (2004). Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J. Neurochem. 89, 1318-1324. doi: 10.1111/j.1471-4159.2004.02423.x.
30. Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., and Zigmond, M. J. (2002). A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099.
31. Pieri, L., Madiona, K., Bousset, L., and Melki, R. (2012). Fibrillar alpha-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J. 102, 2894-2905. doi: 10.1016/j.bpj.2012.04.050.
32. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047. doi: 10.1126/science.276.5321.2045.
33. Quilty, M. C., King, A. E., Gai, W. P., Pountney, D. L., West, A. K., Vickers, J. C., et al. (2006). Alpha-synuclein is upregulated in neurons in response to chronic oxidative stress and is associated with neuroprotection. Exp. Neurol. 199, 249-256. doi: 10.1016/j.expneurol.2005.10.018.
34. Segura-Aguilar, J., Paris, I., Munoz, P., Ferrari, E., Zecca, L., and Zucca, F. A. (2014). Protective and toxic roles of dopamine in Parkinson's disease. J. Neurochem. 129, 898-915. doi: 10.1111/jnc.12686.
35. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841. doi: 10.1126/science.1090278.
36. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840. doi: 10.1038/42166.
37. Van der Perren, A., Van den Haute, C., and Baekelandt, V. (2014). Viral vector-based models of Parkinson's disease. Curr. Topics Behav. Neurosci. 22, 271-301. doi: 10.1007/7854_2014_310.
38. Volles, M. J., Lee, S. J., Rochet, J. C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., et al. (2001). Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819. doi: 10.1021/bi0102398.
39. Wersinger, C., Prou, D., Vernier, P., and Sidhu, A. (2003). Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17, 2151-2153. doi: 10.1096/fj.03-0152fje.
40. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173. doi: 10.1002/ana.10795.
41. Zigmond, M. J., Abercrombie, E. D., Berger, T. W., Grace, A. A., and Stricker, E. M. (1990). Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290-296. doi: 10.1016/0166-2236(90)90112-N.